flow trial semaglutide kidney outcomes 2024 nejm hazard ratio 0.76 clinical (funded by Novo Nordisk): showed 24% reduction in the risk of Preventing chronic kidney disease and

However, it could be unsustainable

Clinically, 0.1% has shown to improve melasma visibly after just 4 weeks

Consequently, diabetic subjects treated with GLP-1 receptor agonists often experience weight loss as opposed to the weight gain commonly induced with other treatment agents

The possibility of offering new hope to individuals struggling with addiction is what makes this work so meaningful. Original study: DOI 10.1038/s41598-025-17927-w Authors: Fatima Quddos, graduate, Virginia Tech Translational Biology, Medicine, and Health Graduate Program Mary Fowler, research assistant and programs coordinator, Fralin Biomedical Research Institute at VTC Ana Carolina de Lima Bovo, Ph.D., postdoctoral associate, Fralin Biomedical Research Institute at VTC Zacarya Elbash, research assistant, Fralin Biomedical Research Institute at VTC Allison N

Additionally, the median time to discontinuation was 279 days for Ozempic, compared to only 120 days for Saxenda